Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Bevacizumab (Avastin)

2009; American Society of Neuroradiology; Volume: 31; Issue: 2 Linguagem: Inglês

10.3174/ajnr.a1987

ISSN

1936-959X

Autores

S.K. Mukherji,

Tópico(s)

Ubiquitin and proteasome pathways

Resumo

SUMMARY: Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.

Referência(s)